Antidiabetic/Insulin Formulation: A New Formulation of Insulin Claimed to be Orally Active

Summary

Novelty: Non-parenteral, pharmaceutical compositions for insulin, based on alkali metal salts of coconut oil, are claimed. Such compositions promote absorption and bioavailability of insulin, and are useful for treating conditions of hyperglycaemia, such as diabetes mellitus.

Biology: These formulations are tested in various animal models (mice, dogs etc) screening for the effects on blood-glucose levels. Results show various degrees of blood-glucose level reduction (ranging from 18.5% reduction in continuous blood-glucose recorded in rats, to 42 - 63% reduction in glucose levels after twenty minutes in dogs, at 10-5 mg potassium cocoate dose levels). The results are presented in diagrammatic format.

Formulation: Formulation details are provided. A typical composition comprises: a) a blood-sugar lowering amount of insulin (20-500 units); b) an alkaline metal cocoate (such as potassium); and c) optionally, a pharmaceutically acceptable carrier (such as a fatty acid selected from a group of caprylic, capric, lauric, palmitic acids etc). The two components, b) and a) are in a ratio of from 500:1 to approximately 1:1, respectively.